An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Status:
Recruiting
Trial end date:
2030-06-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu)
vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC)
progressing after definitive therapy to their primary tumor. The data generated from this
study will provide evidence for the treatment of AAA617 in early-stage prostate cancer
patients to control recurrent tumor from progressing to fatal metastatic disease while
preserving quality of life by delaying treatment with androgen deprivation therapy (ADT).